Dxcover announced that it will be presenting new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
Revolutionary ovarian cancer rapid test available Q4 2022
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
Subscribe To Our Newsletter & Stay Updated
